VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2022 | Targeted therapies for patients with HER2+ colorectal cancer

Jonathan Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the key points from his talk at ESMO WCGIC 2022 on targeted therapies for patients with HER2+ colorectal cancer, including discussions of the HERACLES (NCT03225937) and MOUNTAINEER (NCT03043313) trials. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Disclosures

Consultant or advisory role: Abbvie, Takeda, AstraZeneca, Bayer, GSK, Inivata, Mereo Biopharma, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Viatris, Zentalis Compensated: Yes

Research funding or contracted research: Amgen, Bayer, Erasca, Seagen, Daiichi-Sankyo, Gossamer Bio, AStar D3, Sanofi, Roche/ Genentech, Curegenix, Nektar, Abbvie, Silverback Therapeutics Compensated: No

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter